From early days the sharing of knowledge has been one of the main forces driving science and innovation. Yet latterly, the pharmaceutical industry with its fear of loss of intellectual property has stalled the engine that has given so many beneficial outcomes.
Biochemical kinase profiling using a large panel of kinases with a broad coverage of the human kinome has become the de facto norm within the Pharma industry, demonstrated by the large number of service providers offering outsourced kinase profiling services.
We are in the midst of a revolution in genome engineering, based on reagents that can be designed to cut chromosomal DNA at arbitrary sites. These targetable nucleases allow creation of new mutations at specific sites, introduction of designed sequence changes and production of larger alterations, as desired by the experimenter. They are being used to explore gene function and create disease models and they hold great promise for human gene therapy.
By Dr A Solache, R Brockett, T Chuang, Dr R Clark, R Dimagiba, Dr A Fisher, Dr W Speckmann & Dr C Yang
Antibodies have become a vital tool among researchers in the life sciences and are routinely being used in a number of diverse immunoassay applications, including Western blotting , immunoprecipitation, flow cytometry, enzyme-linked immunosorbent assays, quantitative immunofluorescence) and immunohistochemistry .
Central Nervous System (CNS) disorders bear an economic burden of more than $2 trillion in the US and EU and rake in upwards of $80 billion a year for the pharmaceutical industry. Yet they have become as much a vice as a potential virtue.
The Bio-Pharma business model is undergoing radical changes. Over the last two decades, we have seen a number of changes as the biopharmaceutical industry has gradually become more willing to look externally and embrace the concept of outsourcing as it looks for new sources of discovery and innovation.
The progression from health to disease is marked by significant biological changes within an individual. Clinically presenting symptoms, however, can be non-specific and variable enough to hinder diagnosis, and may appear only after a disease has already become well-established and consequently more difficult to treat.
Specialist 3D cell culture company announced that it is entering into a collaboration with leading stem cell company Roslin Cellab to develop 3D stem cell printing products and services using Alvetex® technology.